Published : 01 Dec 2011
Today Aagami received an assignment from a clinical-stage oncology drug development company from Canada, focused on commercializing new treatments for orphan drug cancers with a high-rate of recurrence following therapeutic intervention with the current standard of care.
The In-Development drug represents a first-in-class bi-functional alkylating agent. It benefits from prior extensive clinical research sponsored by the United States National Cancer Institute (NCI), and is approved as a cancer chemotherapeutic in China since late 1980s for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer.
Its anti-cancer activity is supported by numerous preclinical and more than 40 U.S.-based clinical research publications, including clinical studies supporting activity as a potential treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Based on published & commercial data, company believes that it also has a strong potential to treat a range of cancer indications.
Aagami is quite hopeful for this partnering as India has second highest number of US FDA approved manufacturing facilities, after the US itself and several of Indian leading companies are focused on Oncology.
Also the prevalence of various cancers in India is quite high and due to socio-economic conditions is not well treated in most cases, so we feel confident that this approved in China molecule has high possibilities of Partnering with Indian companies.